Tags

Type your tag names separated by a space and hit enter

Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit.
J Clin Microbiol. 2020 05 26; 58(6)JC

Abstract

Nearly 400,000 people worldwide are known to have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer-probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primer-probe set described by Corman et al. (V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25:2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer-probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.

Authors+Show Affiliations

Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Medicine, University of Washington, Seattle, Washington, USA. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA kjerome@fredhutch.org agrening@uw.edu. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA kjerome@fredhutch.org agrening@uw.edu.

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

32269100

Citation

Nalla, Arun K., et al. "Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit." Journal of Clinical Microbiology, vol. 58, no. 6, 2020.
Nalla AK, Casto AM, Huang MW, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol. 2020;58(6).
Nalla, A. K., Casto, A. M., Huang, M. W., Perchetti, G. A., Sampoleo, R., Shrestha, L., Wei, Y., Zhu, H., Jerome, K. R., & Greninger, A. L. (2020). Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. Journal of Clinical Microbiology, 58(6). https://doi.org/10.1128/JCM.00557-20
Nalla AK, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol. 2020 05 26;58(6) PubMed PMID: 32269100.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. AU - Nalla,Arun K, AU - Casto,Amanda M, AU - Huang,Meei-Li W, AU - Perchetti,Garrett A, AU - Sampoleo,Reigran, AU - Shrestha,Lasata, AU - Wei,Yulun, AU - Zhu,Haiying, AU - Jerome,Keith R, AU - Greninger,Alexander L, Y1 - 2020/05/26/ PY - 2020/03/24/received PY - 2020/04/03/accepted PY - 2020/4/10/pubmed PY - 2020/6/2/medline PY - 2020/4/10/entrez KW - E-gene KW - N2 KW - SARS-CoV-2 KW - primer KW - probe JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 58 IS - 6 N2 - Nearly 400,000 people worldwide are known to have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer-probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primer-probe set described by Corman et al. (V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25:2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer-probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide. SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/32269100/full_citation L2 - http://jcm.asm.org/lookup/pmidlookup?view=long&pmid=32269100 DB - PRIME DP - Unbound Medicine ER -